"Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection"   
NEJM May 16
http://www.nejm.org/doi/full/10.1056/NEJMoa1214853
"CONCLUSIONS

In a single-group study of sofosbuvir combined with peginterferon–ribavirin, patients with predominantly genotype 1 or 4 HCV infection had a rate of sustained virologic response of 90% at 12 weeks. In a noninferiority trial, patients with genotype 2 or 3 infection who received either sofosbuvir or peginterferon with ribavirin had nearly identical rates of response (67%). Adverse events were less frequent with sofosbuvir than with peginterferon. (Funded by Gilead Sciences; FISSION and NEUTRINO ClinicalTrials.gov numbers, NCT01497366 andNCT01641640, respectively.)"